Navigation Links
BiOptix announces expansion of Innovators Program into Europe

BOULDER, Colo. and BASEL, Switzerland, Sept. 26, 2013 /PRNewswire/ -- BiOptix formally announced the European expansion of the BiOptix Innovators Program at MipTec & BioValley Life Sciences Week, being held in Basel, Switzerland from September 24 – 26, 2013.  During the event, the company is launching the BiOptix Innovators Program into Europe, with an emphasis on partnering with key research institutions, pharmaceutical companies and biotechnology/drug discovery firms.  The BiOptix Innovators Program is a unique and innovative product evaluation platform that allows customers to try BiOptix SPR technology independently in their lab, on their timeframe and with complete customer and technical support during the evaluation. 

"This is the third year that BiOptix has participated in MipTec and the BioValley Life Sciences Week in Basel, and the 2013-2014 season brings an opportunity for us to expand our presence in this market with this distinctive program," noted Ken Wilczek, Vice President, Sales & Marketing for BiOptix.  "The life science research corridor in Europe is growing at a substantial rate, and we are excited to be a part of this expansion."  Additional details about the BiOptix Innovators Program can be found at:

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
2. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
3. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
4. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
5. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Pro-Dex, Inc. Announces Fiscal 2013 Fourth Quarter And Full-Year Results
8. OralHygenix Announces Freedom Oral Care System (FOCS) for People with Physical and Mental Disabilities
9. STEMSOFT Announces Release of New Cord Banking Software Solution
10. PipelineRx Announces Expansion into Ten New States with Telepharmacy Services
11. Genarts 18th Annual Film Festival Announces Collaboration With The Partnership At For #endmedicineabuse Project
Post Your Comments:
(Date:11/27/2015)... Research and Markets ( ) has ... Market 2015-2019" report to their offering. ... report, the author the present scenario and growth prospects ... calculate the market size, the report considers revenue generated ... IUDs and copper IUDs. The report forecasts the global ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute ... peer review process that allows practices to demonstrate that they meet or ...
(Date:11/29/2015)... ... November 29, 2015 , ... NewsWatch featured X-wing as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... , It’s the future because flying cars are about to become a reality. Where’s ...
(Date:11/29/2015)... ... 29, 2015 , ... Doctors who missed a case of mesothelioma in a ... mesothelioma and push for a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma ... read it now. , Researchers at Gifu Prefectural Tajimi Hospital in Japan ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing ... December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in San ... Bay Area rental market to efficiently find housing suitable to their needs by showcasing ...
(Date:11/28/2015)... ... 2015 , ... Trying to relax on a couch can actually be uncomfortable, ... this design due to personal experience with a bad back," he said. , This ... as well as increases support. It also makes it easier to eat, do other ...
Breaking Medicine News(10 mins):